Int'l Vaccine Institute to lead clinical trial in Nepal Sanofi and GSK received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. Nepal 01 Oct, 2021
Sanofi, GSK to supply vaccine doses to WHO-backed alliance Have earmarked 200 mln doses of COVID-19 candidate vaccine COVAX alliance also has deals with AstraZeneca, Novavax PARIS: French drugmaker Sanofi and Britain's GlaxoSmithKline will supply 200 million doses of their COVID-19 candidate... Women 28 Oct, 2020
Sanofi, GSK launch trial for COVID-19 protein-based vaccine Phase 1/2 trial enrols 440 adults in the US Final testing stage expected to start in December PARIS: French drugmaker Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine... Environment 03 Sep, 2020
Search for a COVID-19 vaccine heats up in China, US WASHINGTON: Three potential COVID-19 vaccines are making fast progress in early-stage testing in volunteers in China and the US, but it’s still a long road to prove if they'll really work. China’s CanSino Biologics has begun the second phase of... Women 15 Apr, 2020
